- Home
- SCNX vs ITRM Comparison
SCNX vs ITRM Comparison
Compare SCNX & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- ITRM
- Stock Information
- Founded
- SCNX 2010
- ITRM 2015
- Country
- SCNX United States
- ITRM Ireland
- Employees
- SCNX N/A
- ITRM N/A
- Industry
- SCNX Other Pharmaceuticals
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- ITRM Health Care
- Exchange
- SCNX Nasdaq
- ITRM Nasdaq
- Market Cap
- SCNX 59.2M
- ITRM 49.5M
- IPO Year
- SCNX 2020
- ITRM 2018
- Fundamental
- Price
- SCNX $7.92
- ITRM $1.81
- Analyst Decision
- SCNX
- ITRM Strong Buy
- Analyst Count
- SCNX 0
- ITRM 1
- Target Price
- SCNX N/A
- ITRM $5.00
- AVG Volume (30 Days)
- SCNX 13.8K
- ITRM 1.5M
- Earning Date
- SCNX 02-10-2025
- ITRM 11-14-2024
- Dividend Yield
- SCNX N/A
- ITRM N/A
- EPS Growth
- SCNX N/A
- ITRM N/A
- EPS
- SCNX 3.55
- ITRM N/A
- Revenue
- SCNX N/A
- ITRM N/A
- Revenue This Year
- SCNX $1,085.75
- ITRM N/A
- Revenue Next Year
- SCNX N/A
- ITRM N/A
- P/E Ratio
- SCNX $3.23
- ITRM N/A
- Revenue Growth
- SCNX 166.67
- ITRM N/A
- 52 Week Low
- SCNX $3.69
- ITRM $0.81
- 52 Week High
- SCNX $44.56
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- ITRM 49.08
- Support Level
- SCNX N/A
- ITRM $1.63
- Resistance Level
- SCNX N/A
- ITRM $1.95
- Average True Range (ATR)
- SCNX 0.00
- ITRM 0.25
- MACD
- SCNX 0.00
- ITRM -0.09
- Stochastic Oscillator
- SCNX 0.00
- ITRM 16.84
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.